Search

Peptide

Reference library

Educational peptide reference — research use only.

Research & educational use only

For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.

The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.

Semax + Selank Mix

A cognitive blend combining Semax and Selank in neuroprotection research.

Half-life (approx.)
Per-component — short (approx.)
Diluent
Bacteriostatic water (0.9% benzyl alcohol)
Common vials
5, 10 mg

Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.

Overview

A pre-mixed cognitive blend combining Semax and Selank for neuroprotection and anxiolytic research protocols. Intranasal delivery is common in the literature; injectable reconstitution requires protocol-specific validation. Nootropic blend pairing BDNF-upregulating Semax with GABAergic anxiolytic Selank.

Structure & identity

Blend: Semax + Selank

Sequence / structure
Blend: Semax + Selank

Mechanism

Combines BDNF-upregulating (Semax) and anxiolytic (Selank) neuroactive peptides. Combined cognitive and anxiolytic behavioral endpoints in intranasal rodent protocols.

Studies & clinical programs

  • Cognitive + anxiolytic combination rodent studies

    Published research models

    • Peer-reviewed literature documents endpoints under Cognitive + anxiolytic combination rodent studies experimental designs.

Research models in literature

  • Cognitive + anxiolytic combination rodent studies

Literature highlights

  • Combines BDNF-upregulating (Semax) and GABAergic anxiolytic (Selank) neuroactive peptides.
  • Cognitive plus anxiety-behavior endpoints in combined intranasal rodent protocols.
  • Intranasal delivery common in published Russian peptide neuropharmacology literature.

Combination research notes

Intranasal delivery common in published protocols.

Key targets & pathways

BDNFGABAergic systemCognitive-anxiolytic synergyIntranasal blend stability

Research areas

Cognitive blendNeuroprotectionAnxiolytic research

Routes in research literature

IntranasalSubcutaneous

Blend components

Also known as

Semax + Selank MixSemax Selank

Handling cautions

  • Intranasal use common in literature

Stability & storage phases

PhaseConditionGuidance
Lyophilized blendRefrigerated (2–8 °C), sealedConfirm per-peptide mg breakdown on analytical documentation before storage; blended cakes may dissolve more slowly than single-peptide vials.
ReconstitutedBacteriostatic water, refrigeratedGently swirl until all components dissolve; stability limited by the most labile peptide in the mixture — label total and per-component concentration.
Working aliquotsFrozen (−20 °C) aliquots with component ratio notedCalculate per-peptide exposure from verified blend ratios only; do not assume equal mg across components without analytical composition verification.

Stability windows are formulation-dependent — verify published data and your lab SOP.

Reconstitution reference table

Vial (mg)Diluent (mL)mcg/mLUnits @ 100 mcgUnits @ 250 mcgUnits @ 500 mcg
522500.041020
1025000.02510

U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.

Reconstitution steps

  1. Confirm per-peptide composition from analytical documentation before any calculations
  2. Allow vial to reach room temperature (15–30 min)
  3. Swab stopper; inject diluent slowly down vial wall
  4. Gently swirl — blends may take longer to fully dissolve
  5. Label with date, total concentration, and component note
  6. Refrigerate; calculate per-peptide dose from verified ratios

Often used intranasally in research; injectable reconstitution per protocol.

Laboratory record checklist

  • Compound identity recorded in lab notebook (name, lot, preparation date)
  • Analytical identity cross-checked against published sequence or structure
  • Potency or concentration documented from analytical certificate when available
  • Purity or HPLC data filed when provided with research material
  • Appearance noted: intact lyophilized cake or uniform powder
  • Sterility / endotoxin report archived when available
  • Storage temperature applied immediately per published stability guidance